Effect of Erythropoietin on Serum Brain-derived Biomarkers after Carbon Monoxide Poisoning in Rats

Document Type: Original Article


1 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Pharmaceutical Sciences Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran

3 Medical Toxicology Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran


Erythropoietin has been shown to exert neuroprotective effects in a variety of CNS injury models. Elevation of serum S100β, as a glial damage marker and myelin basic protein (MBP) has been reported to occur in acute carbon monoxide (CO) poisoning. The aim of this study was to evaluate the effect of erythropoietin (EPO) on serum S100β and MBP levels after CO poisoning in rats.
Materials and Methods
Rats were poisoned with a mixture of 3000 PPM CO in air for 65 min. After exposure, half of the rats received 5000 u/kg EPO and the rest received normal saline. At 3, 6, 12, 24, 48, 72, 144, and 336 hr after exposure samples were taken. Additionally, EPO was administered at three lower doses (625, 1250 and 2500 u/kg). The serum S100β and MBP levels were measured using immunoenzymatic colorimetric assay. Hemoglobin level was alsomeasured.
Serum S100β levels in CO poisoned rats were significantly higher compared to the control group [6 hr (P< 0.01), 12 hr (P< 0. 001), 24 hr (P< 0.001), 48 hr (P< 0.008) and 72 hr (P< 0.008)]. EPO administration could significantly prevent serum S100β elevations after 12 hr (P< 0.008) and 24 hr (P< 0.008) of CO poisoning. Serum MBP levels in CO poisoned rats were not significantly increased in comparison with the control group (P> 0.05). EPO significantly increased the hemoglobin levels.
EPO could partially prevent neuronal damage. More studies are required to elucidate other aspects of these effects.


1. Omaye ST. Metabolic modulation of carbon monoxide toxicity. Toxicology.  2002; 180:139-150.

2. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322:1111-1122.

3. Schiltz KL. Failure to assess motivation, need to consider psychiatric variables, and absence of comprehensive examination: a skeptical review of neuropsychologic assessment in carbon monoxide research. Undersea Hyperba Med 2000; 27:48-50.

4. Bell MJ, Kochanek PM, Heyes MP, Wisniewski SR, Sinz EH, Clark RSB, et al. Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury. Crit Care Med 1999; 27:493-947.

5. Hans P, Born JD, Chapelle JP, Milbouw G. Creatine kinase isoenzymes in severe head injury. J Neurosurg  1983; 58:689-692.

6. Brvar M, Mozina H, Osredkar J, Mozina M, Brucan A, Bunc M. The potential value of the protein S-100B level as a criterion for hyperbaric oxygen treatment and prognostic marker in carbon monoxide poisoned patients. Resuscitation  2003; 56:105-109.

7. Brvar MMD, Finderle aMDP, Suput DMDP, Bunc MMDP. S100B protein in conscious carbon monoxide-poisoned rats treated with normobaric or hyperbaric oxygen. [Report]. (0090-3493).

8. Vos PE, Lamers KJB, Hendriks JCM, Van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology  2004; 62:1303-1310.

9. Yardan T, Cevik Y, Donderici O, Kavalci C, Yilmaz FM, Yilmaz G, et al. Elevated serum S100B protein and neuron-specific enolase levels in carbon monoxide poisoning. Am J Emerg Med  2009; 27:838-842.

10. Nylén K, Öst M, Csajbok LZ, Nilsson I, Hall C, Blennow K, et al. Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir  2008; 150:221-227.

11. Hergenroeder GW, Redell JB, Moore AN, Dash PK. Biomarkers in the clinical diagnosis and management of traumatic brain injury. Mol Diagn Ther 2008; 12:345-358.

12. Thom SR,Bhopale VM,Fisher D.Hyperbaric oxygen reduces delayed immune-mediated neuropathology in experimental carbon monoxide toxicity. Toxicol Appl Pharmacol 2006; 213:152-159.

13. Ide T, Kamijo Y. Myelin basic protein in cerebrospinal fluid: a predictive marker of delayed encephalopathy from carbon monoxide poisoning.Am J Emerg Med 2008; 26:908-912.

14. Hu M-C, Shiah IS, Yeh C-B, Chen H-K, Chen C-K. Ziprasidone in the treatment of delayed carbon monoxide encephalopathy. Prog  Neuro-Psychopharmacol Biol Psychiatry 2006; 30:755-757.

15. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 952:128-134.

16. Sattler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bahr M, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; 11:S181-S92.

17. Bloomfield S, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocritical Care  2007; 6:121-138.

18. Gunnarson E, Song Y, Kowalewski JM, Brismar H, Brines M, Cerami A, et al. Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. Proc Natl Acad Sci USA 2009; 106:1602-1607.

19. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RHC, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002; 125:1462-1473.

20. Schofield P. Dementia associated with toxic causes and autoimmune disease. Int Psychogeriatr 2005; 17:129-147.

21. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 2002; 91:36-42.

22. Li Y, Hu X, Lu Z. Erythropoietin in the treatment of encephalopathy associated with carbon monoxide poisoning. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:735-738.